Loading institutional data...
Loading institutional data...
Institutional ownership roughly stable: -0.49% change quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $0.70 today, the market must believe free cash flow compounds -1.8%/yr for a decade (off $2M normalized FCF).
2-stage DCF · 0.03B shares · net debt -$2M
mean -505.2% · volatility σ 387% · implied rate exceeded in 0/2 yrs
Central path = implied -1.8%/yr growth; shaded band = ±1σ (387%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Top 30 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.3M 100.0% | $33.0M 100.0% | $43.6M 100.0% | $94.8M 100.0% | $188.4M 100.0% | $81.9M 100.0% | $41.8M 100.0% | $33.3M 100.0% | $34.5M 100.0% | $29.8M 100.0% |
| Cost of Revenue | $38.2M 99.9% | $34.1M 103.1% | $34.5M 79.1% | $66.6M 70.2% | $93.0M 49.4% | $44.9M 54.8% | $27.7M 66.2% | $23.1M 69.3% | $24.5M 71.1% | $19.5M 65.3% |
| Cost of Products | — | — | — | — | — | — | — | — | $21.7M 62.8% | $17.0M 56.9% |
| Gross Profit | $47K 0.1% | -$1.0M -3.1% | $9.1M 20.9% | $28.3M 29.8% | $95.4M 50.6% | $37.0M 45.2% | $14.1M 33.8% | $10.2M 30.7% | $10.0M 28.9% | $10.3M 34.7% |
| Research & Development | $676K 1.8% | $674K 2.0% | $581K 1.3% | $526K 0.6% | $901K 0.5% | $575K 0.7% | $516K 1.2% | $621K 1.9% | $741K 2.1% | $572K 1.9% |
| Selling, General & Admin | $12.8M 33.4% | $13.6M 41.0% | $14.3M 32.8% | $24.0M 25.3% | $17.4M 9.2% | $8.3M 10.1% | $6.4M 15.4% | $6.8M 20.4% | $8.4M 24.2% | $8.8M 29.5% |
| Total Operating Expenses | $21.2M 55.5% | $20.1M 60.7% | $20.6M 47.2% | $29.1M 30.7% | $22.8M 12.1% | $12.9M 15.8% | $11.2M 26.7% | $11.8M 35.5% | $13.8M 39.9% | $13.8M 46.4% |
| Operating Income | -$21.2M -55.3% | -$21.1M -63.9% | -$11.5M -26.4% | -$853K -0.9% | $72.6M 38.5% | $24.1M 29.4% | $3.0M 7.1% | -$1.3M -4.0% | -$3.8M -11.0% | -$3.5M -11.8% |
| Interest Expense | $88K 0.2% | $123K 0.4% | $152K 0.3% | $171K 0.2% | $227K 0.1% | $260K 0.3% | $167K 0.4% | $177K 0.5% | $211K 0.6% | $213K 0.7% |
| Pretax Income | -$12.3M -32.1% | -$3.5M -10.7% | -$8.9M -20.5% | $5.2M 5.4% | $75.0M 39.8% | $26.1M 31.9% | $3.2M 7.6% | -$1.4M -4.1% | -$3.9M -11.4% | -$3.7M -12.4% |
| Income Tax Expense | $291K 0.8% | $8.4M 25.3% | -$1.9M -4.4% | $84K 0.1% | $18.9M 10.0% | $1.9M 2.3% | $8K 0.0% | -$13K -0.0% | -$188K -0.5% | $1K 0.0% |
| Net Income | -$12.6M -32.8% | -$11.9M -36.0% | -$7.0M -16.1% | $5.1M 5.4% | $56.1M 29.8% | $24.2M 29.6% | $3.1M 7.5% | -$1.3M -4.0% | -$3.7M -10.8% | -$3.7M -12.4% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.43 | $-0.40 | $-0.24 | $0.15 | $1.65 | $0.80 | $0.07 | $-0.06 | $-0.14 | $-0.15 |
| EPS (Diluted) | $-0.43 | $-0.40 | $-0.24 | $0.15 | $1.63 | $0.80 | $0.07 | $-0.06 | $-0.14 | $-0.15 |
| Weighted Avg Shares (Basic) | 29.9M | 29.9M | 29.9M | 32.9M | 33.9M | 33.2M | 32.7M | 32.7M | 32.0M | 29.4M |
| Weighted Avg Shares (Diluted) | 29.9M | 29.9M | 29.9M | 33.0M | 34.2M | 33.3M | 32.7M | 32.7M | 32.0M | 29.4M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -17%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $3M covers all $2M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2022-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~9.8% on $895645 of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 14-yr range · 7th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 69.3 | 66.2 | 54.8 | 49.4 | 70.2 | 79.1 | 103.1 | 99.9 |
| Gross Profit | 30.7 | 33.8 | 45.2 | 50.6 | 29.8 | 20.9 | -3.1 | 0.1 |
| R&D | 1.9 | 1.2 | 0.7 | 0.5 | 0.6 | 1.3 | 2.0 | 1.8 |
| SG&A | 20.4 | 15.4 | 10.1 | 9.2 | 25.3 | 32.8 | 41.0 | 33.4 |
| Operating Income | -4.0 | 7.1 | 29.4 | 38.5 | -0.9 | -26.4 | -63.9 | -55.3 |
| Income Tax | -0.0 | 0.0 | 2.3 | 10.0 | 0.1 | -4.4 | 25.3 | 0.8 |
| Net Income | -4.0 | 7.5 | 29.6 | 29.8 | 5.4 | -16.1 | -36.0 | -32.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on RVP: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| RVP | $20M | — | — | 0.5× | 15.8% | 0.1% | -32.8% | -16.9% | -16.7% | -0.1× | 29 |
Peers = companies sharing RVP's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.